TEST BANK FOR NURSING PHARMACOLOGY, 2ND EDITION BY MICHELLE ERNSTMEYER AND ELIZABETH CHRISTMANQUESTIONS & 100% VERIFIED ANSWERS AND RATIONALES | GRADED A+LATEST UPDATE

TEST BANK FOR NURSING PHARMACOLOGY, 2ND EDITION
BY MICHELLE ERNSTMEYER AND ELIZABETH
CHRISTMANQUESTIONS & 100% VERIFIED ANSWERS AND
RATIONALES | GRADED A+LATEST UPDATE

, TABLE OF CONTENTS

Textbook chapters
cf




 Chapter 1:Pharmacokinetics &Pharmacodynamics: Includes basic concepts such as
cf cf c f cf fc c f c f cf cf cf




absorption, distribution, metabolism, and excretion.
cf c f c f c f cf




 Chapter 2:Legal/Ethical: Covers safe medication administration, legal guidelines, and
cf cf c f cf cf c f c f cf c f




preventing medication errors.
cf c f c f




 Chapter 3:Antimicrobials: Focuses on various antimicrobial therapies, including
cf cf fc cf cf cf cf fc cf c f




penicillins, cephalosporins, antivirals, and antifungals.
cf c f c f c f cf




 Chapter 4:Autonomic Nervous System: Discusses medications related to the
cf cf c f cf cf c f c f cf cf




autonomic nervous system, including agonists and antagonists.
cf c f cf c f c f c f cf




 Chapter 5:Respiratory System: Covers medications used for respiratory disorders,
cf cf cf cf cf c f cf cf c f




such as antihistamines, decongestants, and corticosteroids.
cf cf cf c f c f cf




 Chapter 6:Cardiovascular &RenalSystems:Addresses medications for the
cf cf c f cf cf cf cf c f cf




cardiovascular and renal systems, including antiarrhythmics, diuretics, and
cf c f cf cf c f c f c f c f




antihypertensives.
cf




 Chapter 7:Gastrointestinal System:Focusesonmedications for the GIsystem, such as
cf cf cf cf cf cf c f cf cf cf cf cf




antiulcer medications, laxatives, and antiemetics.
cf c f c f c f cf




 Chapter 8:Central Nervous System: Covers CNSdepressants, stimulants,
cf cf c f cf cf cf cf c f




antidepressants, and anticonvulsants.
cf c f cf




 Chapter 9:Endocrine System: Explores endocrine medications, including
cf cf c f cf cf c f c f




corticosteroids, antidiabetics, and thyroid medications.
cf c f c f cf c f




 Chapter 10:Analgesics&MusculoskeletalSystem: Includes nonopioid and opioid
cf cf cf cf fc cf c f c f cf




analgesics, as well as anesthetics.
cf c f cf c f cf

,CHAPTER1 — PHARMACOKINETICS& PHARMACODYNAMICS fc cf cf fc cf




Question1 fc




Anurseis teaching a newly licensed nurse aboutdrug absorption.Which factor
fc cf cf cf cf c f cf cf fc cf fc cf




primarily affects the rate ofabsorptionafter oral administration?
cf c f cf cf cf cf cf cf cf




A. Volume ofdistribution cf cf




B. Gastricemptying time cf c f




C. Hepatic enzyme activity cf cf




D. Protein binding cf




Correctanswer:B. Gastricemptying time
fc fc cf cf cf




Rationale:
cf




 B is correct.Gastric emptying time determines how quickly an orally
cf cf fc cf c f c f c f cf cf cf




cf administered drugreaches thesmall intestine, where mostabsorptionoccurs; cf cf cf cf cf c f cf fc fc




cf faster emptying → more rapid absorption. cf cf cf cf cf




 A(Volumeofdistribution)affectsdistribution, notinitial absorptionrate.
fc fc cf cf fc cf fc c f fc




 C(Hepaticenzyme activity) influences metabolism (first-pass effect)and
fc fc cf cf c f cf cf cf




cf clearance, not the absorption rate from the GI tract. c f cf cf cf cf cf cf cf




 D(Proteinbinding) affects freedrugavailable fordistribution andaction,
fc fc cf cf cf cf c f cf cf cf




not the physical process/rateof absorption across the GI mucosa.
cf cf cf cf cf cf cf cf cf cf




Question2 fc




A68-year-old patient with decreased renal function is prescribeda drug that is
cf c f cf cf cf cf cf c f fc cf cf cf




90%renally excretedunchanged. Whichpharmacokinetic changeis mostlikely and
cf fc cf cf cf fc cf cf cf fc cf




cf requires nurse action? cf cf




A. Increasedhepatic metabolism leading tosubtherapeutic levels cf cf cf c f cf cf

, B. Decreasedhalf-life requiring morefrequent dosing cf c f cf cf cf




C. Accumulation ofthe drugcausing toxicity cf fc cf fc cf




D. Increasedfirst-passeffectreducing bioavailability fc fc cf cf




Correctanswer:C. Accumulationof the drug causingtoxicity Rationale:
fc fc cf cf cf cf cf cf cf




 C is correct.Impaired renal excretion leads to decreased clearance of renally
cf cf cf c f cf cf cf cf cf c f cf




cf eliminated drugsandincreasedaccumulation →higher plasmalevels and c f fc fc fc cf fc cf cf cf




potential toxicity. Nurse should notify prescriber and anticipate dose reduction
cf cf cf cf cf cf cf cf cf cf




or extended interval.
cf cf cf




 A(Increasedhepaticmetabolism)is unrelated torenal excretion.
fc fc fc fc cf c f cf cf




 B(Decreasedhalf-life)is oppositeofexpected; renal impairment typically
fc fc fc cf fc cf cf cf c f




increases half-life. cf




 D(Increasedfirst-passeffect)refers to hepatic metabolism and would
cf fc fc cf cf cf c f cf cf




decreasebioavailability; notthe primary issue with renal impairment.
cf fc c f fc cf cf cf cf cf




Question3 fc




Whichstatement bestdescribesvolume ofdistribution (Vd)?
fc cf fc fc cf cf cf




A. Vdindicates howrapidly a drug is absorbedfromthe GI tract.
fc cf cf c f cf cf cf fc fc cf cf




B. Ahigh Vdsuggestsextensive distribution into tissues.
fc cf fc fc cf cf cf




C. Vdis adirect measureofplasmaprotein binding.
cf cf cf cf cf cf cf cf




D. Vdequals thepercentage ofdrugeliminated bythekidneys.
fc cf fc cf fc fc c f cf fc




Correctanswer:B. A high Vd suggests extensive distribution into tissues.
fc fc cf cf cf cf cf cf cf cf




Rationale:
cf